Burde Kaustubh Girish, Nair Indu R, Keechilattu Pavithran, Rajanbabu Anupama
Department of Gynaecological Oncology, Amrita Institute of Medical Sciences, Kochi, Kerala 682024 India.
Department of Gynaecological Oncology, GCRI, Ahmedabad, Gujarat India.
J Obstet Gynaecol India. 2025 Apr;75(Suppl 1):135-145. doi: 10.1007/s13224-024-02034-z. Epub 2024 Aug 21.
In India, the incidence of uterine cancer is 17,420 per year. Presence of mismatch repair genes is one of the risk factors which can cause microsatellite instability in DNA leading to hereditary syndromes as well as sporadic cancer. In the present study, we aim to determine the prevalence of MMR gene mutations by IHC staining for MMR proteins in endometrial cancer. We further aim to corelate various clinic-pathological features with mismatch repair gene defect (MMRd) cancers and to determine its effects recurrence and survival in endometrial cancer.
This is an ambispective study of a retrospectively selected cohort followed up prospectively. It was conducted in the Department of Gynaecological Oncology, AIMS. The cohort was evaluated for the four MMR proteins via IHC staining, and their various clinic-pathological factors were studied. Also, the factors affecting their recurrence free survival (RFS) and overall survival (OS) were observed.
The prevalence of MMR loss in endometrial cancer patients was 31.34%. Most common loss of MMR gene was MLH1 and PMS 2 (57.14%). We did not find any significant differences pertaining to age, BMI, menstrual status, family history and second malignancies in both groups of endometrial cancers. While comparing the histopathological characteristics, no significant difference was found regarding to histopathology, stage, type, grade, P53 status, tumour size, lymph node involvement and LVSI status. No significant difference was seen between two groups in RFS and OS.
We found a significant proportion of endometrial cancers with defective MMR genes in Indian population. We did not find any correlation of MMR to the various clinical and histopathological factors that we analysed. MMRd did not significantly affect the RFS and OS in endometrial cancers.
在印度,子宫癌的发病率为每年17420例。错配修复基因的存在是导致DNA微卫星不稳定从而引发遗传性综合征以及散发性癌症的危险因素之一。在本研究中,我们旨在通过免疫组化染色检测子宫内膜癌中错配修复蛋白来确定错配修复基因突变的患病率。我们还旨在将各种临床病理特征与错配修复基因缺陷(MMRd)癌症相关联,并确定其对子宫内膜癌复发和生存的影响。
这是一项对回顾性选择的队列进行前瞻性随访的双向研究。研究在全印医学科学研究所妇科肿瘤学系开展。通过免疫组化染色评估该队列中的四种错配修复蛋白,并研究其各种临床病理因素。此外,观察影响其无复发生存期(RFS)和总生存期(OS)的因素。
子宫内膜癌患者中错配修复缺失的患病率为31.34%。最常见的错配修复基因缺失是MLH1和PMS 2(57.14%)。我们发现两组子宫内膜癌在年龄、体重指数、月经状况、家族史和第二原发恶性肿瘤方面没有显著差异。在比较组织病理学特征时,在组织病理学、分期、类型、分级、P53状态、肿瘤大小、淋巴结受累和淋巴血管间隙浸润状态方面未发现显著差异。两组在RFS和OS方面也未发现显著差异。
我们发现印度人群中有相当比例的子宫内膜癌存在错配修复基因缺陷。我们未发现错配修复与我们分析的各种临床和组织病理学因素之间存在任何关联。MMRd对子宫内膜癌的RFS和OS没有显著影响。